በሜሪላንድ ለቢ-ሴል ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች
ለቢ-ሴል ሊምፎማ የሚደረጉ 7 ጥናቶች በሜሪላንድ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በሜሪላንድ ውስጥ ያሉ ከተሞች
Official study text (English)
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ3 እስከ 39 · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT05442515A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- The University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06742996Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
- Walter Reed National Military Medical Center, Bethesda
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 4 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT07652580Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 120 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT05389423A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- American Oncology Partners of Maryland, PA, Bethesda
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT05254743DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ጁላይ 2026 · NCT04792489Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Johns Hopkins University, Baltimore
- National Cancer Institute, Pediatric Oncology Branch, Bethesda
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ1 እስከ 21 · ሁሉም ጾታዎች · የተሻሻለው በ6 ዲሴም 2024 · NCT05476770ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።